Justet Aurelien, Ottaviani Sebastien, Dieudé Philippe, Taillé Camille
Department of Service de Pneumologie A, Hôpital Bichat-Claude Bernard, Paris, France Université Denis Diderot, Paris 7, Unité INSERM U1152, Paris, France.
Department of Service de Rhumatologie, Hôpital Bichat Claude Bernard, Paris, France.
BMJ Case Rep. 2015 May 14;2015:bcr2014209076. doi: 10.1136/bcr-2014-209076.
Lung involvement in primary Sjögren syndrome occurs in approximately 10-20% of patients. Tocilizumab, an anti-interleukin-6 receptor antibody, has demonstrated efficacy and safety in small series of systemic sclerosis, and systemic lupus erythematosus, but its effect on interstitial lung manifestations of connective tissue diseases is not well known. We report the use of tocilizumab in a refractory organising pneumonia associated with Sjögren's disease. Our observation suggests that tocilizumab could be an alternative therapeutic in refractory organising pneumonia.
在原发性干燥综合征患者中,肺部受累的发生率约为10%-20%。托珠单抗是一种抗白细胞介素-6受体抗体,已在小样本系统性硬化症和系统性红斑狼疮患者中显示出疗效和安全性,但其对结缔组织病间质性肺表现的影响尚不清楚。我们报告了托珠单抗在与干燥综合征相关的难治性机化性肺炎中的应用。我们的观察表明,托珠单抗可能是难治性机化性肺炎的一种替代治疗方法。